期刊文献+

新辅助化疗在宫颈癌治疗中的应用 被引量:1

Application of Neoadjuvant Chemotherapy in the Treatment of Cervical Cancer
下载PDF
导出
摘要 目的评价新辅助化疗在宫颈癌治疗中的效果,为宫颈癌治疗工作的开展提供参考。方法选择我院2016年8月~2018年3月收治的宫颈癌患者60例。以随机数字表法分为对照组和观察组,各30例。对照组接受常规手术治疗,观察组在术前给予新辅助化疗治疗。对比两组宫颈癌患者术中出血量、手术时间、治疗效果以及术后并发症情况、患者治疗效果满意度评分。结果观察组宫颈癌患者手术时间为(144.50±23.50)min,短于对照组的(224.50±28.50)min(P<0.05);术后并发症总发生率为16.67%,低于对照组的6.66%(P<0.05);观察组治疗效果满意度评分(90.02±2.15)分,高于对照组的(75.50±2.80)分(P<0.05);治疗总有效率86.67%,优于对照组的73.33%(P<0.05)。结论宫颈癌治疗中于术前进行新辅助化疗,可以提高患者治疗效果、安全性、缩短手术时间,整体预后效果显著。 Objective To evaluate the effect of neoadjuvant chemotherapy in the treatment of cervical cancer and provide reference for the development of cervical cancer treatment.Methods 60 patients with cervical cancer admitted to our hospital from August 2016 to March 2018 were selected. They were divided into control group and observation group by random number table method, 30 cases each. The control group received routine surgery and the observation group received neoadjuvant chemotherapy before surgery. The intraoperative blood loss, operation time, treatment effect, postoperative complications, and patient satisfaction satisfaction scores of the two groups of cervical cancer patients were compared.Results The operation time of cervical cancer patients was (144.50±23.50) min, which was shorter than that of the control group (224.50±28.50) min (P<0.05). The total incidence of postoperative complications was 16.67%, which was lower than that of the control group 6.66%(P<0.05). The satisfaction score of the treatment group (90.02±2.15) was higher than that of the control group (75.50±2.80)(P<0.05);the total effective rate of treatment was 86.67%, which was better than 73.33% of the control group (P<0.05).Conclusion Neoadjuvant chemotherapy in the treatment of cervical cancer can improve the treatment effect, safety and shorten the operation time. The overall prognosis is significant.
作者 李博 李春晓 LI Bo;LI Chun-xiao(Department of Oncology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China;Department of General Surgery,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
出处 《医学信息》 2019年第15期106-108,共3页 Journal of Medical Information
关键词 新辅助化疗 手术治疗 宫颈癌 术后并发症 Neoadjuvant chemotherapy Surgical treatment Cervical cancer Postoperative complications
  • 相关文献

参考文献6

二级参考文献80

  • 1安云婷,李隆玉,邓克华,李汉萍,罗兵,舒宽勇,潘玫,万磊.紫杉醇联合顺铂/卡铂在宫颈癌新辅助化疗中的作用[J].实用癌症杂志,2006,21(5):499-501. 被引量:13
  • 2Roberto A,Francesco P,Roberto M,et al.Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer[J].Gynecol Oncol,2012,127:290-296.
  • 3Park DC,Kim JH,Lew YO,et al.Phase II trial of neo-adjuvant paclitaxel and cisplatin in uterine cervical cancer[J].Gynecol Oncol,2004,92:59-63.
  • 4Kamoi S,Ohaki Y, Amano Y,et al. Pre -treatment mitotic indexversus computer-quantitated Ki -67 nuclear antigen labeling indexas predictors of response to neoadjuvant chemotherapy in uterinecervical carcinoma[J]. J Nippon Med Sch,2003,70( 3): 219-226.
  • 5Snitcovsky I,LeitSo GM,Pasini FS,et al. Plasma osteopontin levelsin patients with head and neck cancer undergoing chemoradiotherapy[J]. Arch Otolaryngol Head Neck Surg,2009,135(8):807-811.
  • 6Semenza GL. Hypoxia -inducible factors : mediators of cancerprogression and targets for cancer therapy [J]. Trends Pharmacol Sci,2012,33(4):207-214.
  • 7Harirah H, Donia SE,Hsu CD. Serum soluble Fas in the syndrome ofhemolysis, elevated liver enzymes, and low platelets [J]. ObstetGynecol,2001,98(2): 295-298.
  • 8Qiuping Z,Jei X, Youxin J,et al. CC chemokine ligand 25 enhancesresistance to apoptosis in CD4 + T cells from patients with T -celllineage acute and chronic lymphocytic leukemia by means of livinactivation[J]. Cancer Res, 2004,64( 20) :7579-7587.
  • 9Xie J, Xiong L,Tao X,et al. Anti tumor effects of murine bonemarrow-derived dendritic cells infected with xenogeneic livin alpharecombinant adenoviral vectors against Lewis lung carcinoma [J].Lung Cancer,2010,68(3) :338-345.
  • 10Cmkovic-Mertens I, Hoppe—Seyler F,Butz K. Induction of apoptosisin tumor cells by siRNA -mediated silencing of the livin/ML-IAP/KIAP gene [J]. Oncogene,2003,22(51):8330-8336.

共引文献89

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部